Insights

Strategic Partnerships OS Therapies is actively engaging with investors, strategic partners, and industry collaborators as evidenced by planned conference participation (Moody Capital Solutions 2026) and a US commercialization partner (EVERSANA) for OST-HER2, indicating strong outbound BD potential for distribution, co-development, and licensing opportunities.

Clinical Momentum With OST-HER2 in a Phase IIb trial showing improved Event Free Survival and early Overall Survival, there is a clear near-term clinical readout pathway that can attract CROs, contract manufacturers, and investor/deal interest focused on scalable manufacturing, trial services, and risk-sharing partnerships.

Financial Readiness Recent convertible promissory notes financing and a filed/ongoing funding round demonstrate accessible capital channels and a readiness to engage potential lenders, strategic investors, and debt/equity financing partners to support clinical development and potential commercial launch activities.

Therapeutic Focus Dual platform approach OST-HER2 and OST-tADC targets solid tumors including osteosarcoma and breast cancer, presenting multiple avenues for collaboration with biotech manufacturers, device/diagnostic partners, and specialty contract manufacturing organizations that can support complex biologics or conjugates.

Market Outreach Active participation in industry events and a recent advisory appointment (Chief Medical Advisor) signals a proactive market-facing stance, offering sales teams a touchpoint to coordinate with clinical leadership, leverage thought leadership, and identify payer and distributor engagement opportunities.

Similar companies to OS Therapies

OS Therapies Tech Stack

OS Therapies uses 8 technology products and services including UserWay, Reddit Ads, Twitter Ads, and more. Explore OS Therapies's tech stack below.

Media & News

OS Therapies's Email Address Formats

OS Therapies uses at least 3 email formats:
OS Therapies Email FormatsExamplePercentage
FL@ostherapies.comJD@ostherapies.com
82%
FLast@ostherapies.comJDoe@ostherapies.com
9%
First@ostherapies.comJohn@ostherapies.com
9%

Frequently Asked Questions

What is OS Therapies's official website and social media links?

Minus sign iconPlus sign icon
OS Therapies's official website is ostherapies.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does OS Therapies generate?

Minus sign iconPlus sign icon
As of November 2026, OS Therapies's annual revenue is estimated to be <$1M.

What is OS Therapies's SIC code and NAICS code?

Minus sign iconPlus sign icon
OS Therapies's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does OS Therapies have currently?

Minus sign iconPlus sign icon
As of November 2026, OS Therapies has approximately 11 employees across 1 continents, including North America. Key team members include Chief Commercial Officer: K. C. and Chief Medical And Scientific Officer For Os Therapies: R. P. Explore OS Therapies's employee directory with LeadIQ.

What industry does OS Therapies belong to?

Minus sign iconPlus sign icon
OS Therapies operates in the Biotechnology Research industry.

What technology does OS Therapies use?

Minus sign iconPlus sign icon
OS Therapies's tech stack includes UserWay, Reddit Ads, Twitter Ads, Squarespace, Squarespace Commerce, Google Cloud, Mautic and WP Engine.

What is OS Therapies's email format?

Minus sign iconPlus sign icon
OS Therapies's email format typically follows the pattern of FL@ostherapies.com. Find more OS Therapies email formats with LeadIQ.

How much funding has OS Therapies raised to date?

Minus sign iconPlus sign icon
As of November 2026, OS Therapies has raised $46M in funding. The last funding round occurred on Aug 10, 2026 for $4.2M.

When was OS Therapies founded?

Minus sign iconPlus sign icon
OS Therapies was founded in 2018.
OS Therapies logo

OS Therapies

Biotechnology ResearchNew York, United States11-50 Employees

OS Therapies is a clinical-stage biotechnology research company focused on therapies for osteosarcoma, breast cancer, and other solid tumors. Its two platform approaches aim to prevent metastasis and to debulk tumors, with OST-HER2 advancing in a Phase IIb/III-like development and OST-tADC pursuing a novel pre-clinical drug conjugate strategy that activates in the acidic cancer environment. The company operates from New York, NY, and maintains a relatively small team dedicated to developing targeted cancer treatments. As part of its work, OS Therapies engages in collaborations and participates in industry events to share clinical data and explore commercialization pathways. A recent development includes the appointment of a chief medical advisor, reflecting ongoing scientific leadership and clinical oversight.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $46M

    OS Therapies has raised a total of $46M of funding over 10 rounds. Their latest funding round was raised on Aug 10, 2026 in the amount of $4.2M as a Post IPO Debt.

  • <$1M

    OS Therapies's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.